Newly-discovered and future biomarkers are likely to help oncologists give an accurate prognosis and to prescribe more effective treatment for patients with multiple myeloma.
Immunotherapy may be effective for some patients with NSCLC as a second-line treatment, but it's unclear the role it will have in the first-line.
Inhibiting the VEGF signaling pathway can cause hypertension; there are, however, limited data on managing kinase inhibitor-induced hypertension.
A newly released survey of clinical testing finds that widely divergent methodologies for MRD testing remain a continuing challenge.
Speakers at the 2016 Concordia Summit's panel, "Precision Medicine in Cancer Research," discussed the importance and future of immunotherapy for cancer treatment.
Researchers are attempting to determine the usefulness of mindfulness for cancer pain.
Overselling scientific data contributes to misunderstanding, failure, and disappointment in real-world settings.
Novel targeted and immunological therapies may help improve the outlook for patients with renal cell carcinoma (RCC).
Checkpoint Inhibitors and Combination Therapy: the Future of Treatment for Non-small Cell Lung Cancer?
While immune checkpoint inhibitors show real promise for treating lung cancer, better predictive biomarkers are necessary to make the therapy more effective.
Breast cancer-specific distress, though offset by psychosocial adjustment, is higher among adolescents at high risk of developing breast cancer.
It is the responsibility of investigators to develop randomized trials that investigate rare subtypes of RCC, according to an editorial.
Whole brain radiotherapy does not improve overall survival or quality of life among patients with brain-metastatic lung cancer.
Authors of a modeling study recommend triennial mammography for 12% of women aged 50 years, and 20% aged 65 years with low breast density and few or no risk factors.
An analysis of over 20 years of health data indicates that exposure to air pollution is correlated with worsened survival outcomes for patients diagnosed with lung cancer.
Research has uncovered a potential treatment target for mutant KRAS non-small cell lung cancer: Acyl-Coenzyme A synthetase long chain family member 3.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Statins Linked to Improved Overall Survival in Multiple Myeloma
- Immune Checkpoint Inhibitors Continue to Transform Management of Advanced NSCLC
- Ghost and Honorary Authorship in Cancer Research
- Oral REP Regimen Active in Myeloma Refractory to Lenalidomide
- Minimal Residual Disease and Treatment Response in Multiple Myeloma
- PSA Testing Unchanged in Years After USPSTF Recommendation
- Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy
- MRI May Be Effective Screening Test for Hepatocellular Carcinoma
- Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP
- Emerging Prognostic Markers Continue to Improve Myeloma Treatment